Thea Pharma UK

What Thea Pharma UK does

Théa Pharma UK (legal entity: Théa Pharmaceuticals Limited) is a UK-based pharmaceutical company solely dedicated to ophthalmology, established in 2008 as a wholly owned subsidiary of France's Laboratoires Théa SAS. The company markets, distributes, and provides medical education support for over 30 ophthalmic products across prescription (glaucoma, anti-inflammatory, anti-infective, allergy, surgical pharmaceuticals) and non-prescription (dry eye, blepharitis/MGD, eye nutritionals) categories in the UK and Ireland. Its core technological differentiator is the patented ABAK multi-dose preservative-free delivery system, complemented by Steri-free, Easy Grip, Protriaxin vehicle, and carbomer gel formulation technologies, all originating from the parent group's R&D. Thea pioneered first-to-market preservative-free formulations in several categories including prostaglandin monotherapy (Monopost), fixed-combination glaucoma therapy (Fixapost), a 3-day topical antibiotic (Azyter), and the first licensed intracameral mydriatic/anaesthetic combination for cataract surgery (Mydrane).

The company operates a sales-led go-to-market model targeting three healthcare professional segments: optometrists, ophthalmologists, and hospital eye surgery services, with parallel distribution to community pharmacies for dispensed prescriptions and OTC sales. Pricing is not publicly disclosed; revenue is generated through standard pharmaceutical one-time-sale transactions via wholesale distribution to community pharmacies and direct sales to NHS hospital pharmacies. Demand generation is anchored in HCP education, primarily through the Théa Academy CPD-accredited online learning platform and a calendar of sponsored clinical events (Moorfields International Glaucoma Symposium, Birmingham Corneal Meeting, Simulated Ocular Surgery Masterclass, national webinar series). The company is privately held under long-term family ownership (Chibret family) and is operationally structured into three business units: Consumer, Medical, and Surgical.

Since 2008, Thea has scaled from 5 to over 50 employees and relocated twice, most recently to purpose-built offices at the IC5 Innovation Centre on Keele University Science and Innovation Park in 2018. Strategic growth has been driven by a mix of portfolio acquisitions (Mydriasert in 2011; Otrivine Antistin, Zaditen, and Voltarol Ophtha in 2012) and organic product launches. The Clinic Takeover programme extends commercial reach into community pharmacy service delivery, while the company is in active compliance with the UK Modern Slavery Act and publishes an annual Carbon Reduction Plan.

Name

Thea Pharma UK

Legal name

Théa Pharmaceuticals Limited

Website

https://thea-pharmaceuticals.co.uk

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Théa Pharma UK is a privately held, family-owned ophthalmic pharmaceutical subsidiary distributing 30+ prescription and non-prescription products, all preservative-free, to optometrists, ophthalmologists, NHS hospitals, and community pharmacies across the UK and Ireland.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Ophthalmic pharmaceuticals
• Preservative-free eye drops
• Glaucoma medications
• Cataract surgery products
• Dry eye treatment

Headquarters

HQ city

Keele

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Revenue from prescription-only medicines for glaucoma, inflammation, infection, and allergy treatment sold to NHS hospitals, community pharmacies, and dispensed directly to patients via healthcare professionals.
2. Non-Prescription (OTC) Products: Revenue from over-the-counter products for dry eye, blepharitis, meibomian gland dysfunction, and eye nutritionals sold through pharmacies and directly to consumers.
3. Surgical Pharmaceuticals: Revenue from cataract surgery products including intracameral antibiotics and mydriatic inserts used in hospital settings.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Théa Pharmaceuticals UK manufactures and distributes a portfolio of over 30 ophthalmic prescription and non-prescription products for healthcare professionals and community pharmacies. The range covers glaucoma, anti-inflammatory, anti-infective, allergy, cataract surgery pharmaceuticals, dry eye, blepharitis management, lid hygiene and eye nutritionals, with a unifying focus on preservative-free formulations.

Product overview

Théa Pharmaceuticals Limited is an innovative company solely dedicated to developing high-quality ophthalmic products across the UK and Ireland. The company offers over 30 products across key therapy areas, including both prescription and non-prescription options that are free from preservatives. Prescription products cover Glaucoma (Monopost, Fixapost, Tiopex), Inflammation (Dexafree, Softacort, Voltarol Ophtha), Infection (Azyter, Virgan), Allergy (Zaditen), and Surgical Pharmaceuticals (Aprokam, Mydrane, Mydriasert). Non-prescription products address Dry Eye (Thealoz Duo, Thealoz Duo Gel, Thealoz, Hyabak, Liquivisc), Blepharitis/MGD (Blephasol, Blephaclean, Blephagel, Blephasteam, Blephademodex, Blepha EyeBag), and Eye Nutritionals (Nutrof Total, Hyabak Caps). The portfolio is unified by Théa's pioneering ABAK bottle technology enabling preservative-free formulations across the range.

Differentiator

Problem solved

Functional benefit

Brands

• Théa Academy: Online education platform for healthcare professionals offering courses, webinars, and educational resources in eye care and ophthalmology.

Products and services

• Thealoz Duo Preservative-free eye drops containing trehalose and sodium hyaluronate in the ABAK bottle for protection and long-lasting hydration of the ocular surface; for patients with dry eye.
• Thealoz Duo Gel Gel formulation of Thealoz Duo for patients with more severe dry eye symptoms who prefer a gel format or for night-time use.
• Thealoz Preservative-free eye drops containing trehalose with bioprotective properties to protect corneal and conjunctival epithelia from desiccation.
• Hyabak Preservative-free sodium hyaluronate dry eye drops in the ABAK bottle system, making preservative-free a cost-effective option.
• Hyabak Caps Nutritional supplement containing high dose of Omega 3 and 6 fatty acids to support dry eye sufferers.
• Nutrof Total Eye nutrition supplement containing resveratrol, lutein, zeaxanthin and omega 3 to generally support eye health and help maintain vision.
• Blephasol Lid hygiene solution for conditions such as MGD and blepharitis.
• Blephaclean CE-marked lid hygiene wipe with clinical evidence supporting use in blepharitis patients and lowering bacterial load on eyelids.
• Blephagel PF Preservative-free gel for lid hygiene using SteriFree tube technology.
• Blephademodex Clinically proven wipe to combat demodex mite infestation.
• Blepha EyeBag Clinically proven medical device for treatment of blepharitis, styes, chalazion and meibomian gland dysfunction.
• Blephasteam First comprehensive moist heat therapy for management of Meibomian Gland Dysfunction and associated diseases.
• Monopost First preservative-free prostaglandin in single dose format for treatment of glaucoma using innovative vehicle protriaxin.
• Fixapost First preservative-free latanoprost-timolol fixed combination in single-dose format.
• Tiopex Novel once-daily preservative-free timolol in carbomer gel enhancing residence time.
• Aprokam Intracameral antibiotic (cefuroxime) for prophylaxis of endophthalmitis in cataract surgery.
• Mydrane First licensed intracameral mydriatic and anaesthetic combination for cataract surgery to obtain pupil dilation and intraocular anaesthesia.
• Mydriasert Ophthalmic insert for mydriasis used in cataract surgery to support more efficient services.
• Dexafree Low cost, preservative-free dexamethasone eye drops.
• Softacort First preservative-free topical hydrocortisone eye drops for mild non-infectious conjunctival inflammation.
• Azyter First 3-day topical antibiotic treatment, preservative-free, licensed for adults and children over 3 months.
• Zaditen Anti-allergy eye drops for hay fever and allergy management.
• Théa Academy Moodle-based online learning management system providing CPD courses, webinars, clinical resources, and event recordings for optometrists, ophthalmologists, nurses and pharmacists; accredited by GOC, GMC, GPhC, NMC.

Quantifiable outcome

• ABAK bottle contents usable for up to 6 months after opening (vs 2-4 weeks for preserved bottles)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Laboratoires Théa SAS (Parent Company)coreOthersThéa Pharmaceuticals UK is a subsidiary of Laboratoires Théa SAS, a privately owned company solely dedicated to ophthalmology and owned by the Chibret family, based in Clermont-Ferrand, France. The parent company has 150+ years of heritage in ophthalmology innovation. Théa UK operates under the Open Innovation programme led by Jean-Frederic Chibret.

Scale indicators5 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Santen Pharmaceutical: Japan-headquartered ophthalmology specialist focused on prescription glaucoma, dry eye, and ocular-surface products across Europe; comparable as a specialty ophthalmology pharma with similar therapy-area mix and HCP-led model.
• Scope Ophthalmics: UK-based specialty ophthalmology company focused on dry eye, lid hygiene, and ocular-surface products; comparable as a similarly sized UK player selling OTC and prescription eye-care products through the same community-pharmacy and optometrist channels.
• Laboratoires Théa SAS: The French parent group and global operator of the Théa brand; directly comparable as the broader platform whose UK business is a national subsidiary, with shared product portfolio, R&D, and ABAK technology.

Broad incumbents

• Alcon: Largest dedicated eye-care company globally with a strong UK pharmaceutical and surgical footprint; directly comparable in cataract-surgery adjacencies, dry eye, and glaucoma categories, and a likely competitor for hospital contracts.
• Allergan (AbbVie): Global ophthalmology major with broad dry-eye, glaucoma, and aesthetics franchises; directly comparable in glaucoma and ocular-surface categories where Théa competes, but with much larger scale and a wider portfolio.
• Bausch + Lomb: Global ophthalmic pharmaceuticals, surgical, and vision-care company with significant UK presence; comparable across glaucoma, dry eye, and surgical adjacencies, with a broader portfolio spanning consumer and surgical devices.

Emerging players

• NovaBay Pharmaceuticals: US-listed ophthalmology company commercialising prescription eye-care products including Aganocide and anti-infectives; comparable as a smaller specialty pharma with HCP-led distribution and similar anti-infective and ocular-surface categories.
• Nicox: European ophthalmology company with a glaucoma and ocular-surface portfolio (including preservative-free programmes); comparable as a specialty pharma competing in similar therapy areas with a similar HCP-led commercial model.
• Visufarma: European ophthalmic company with a growing presence in dry eye, lid hygiene, and ocular nutrition; comparable as a smaller specialty player targeting the same optometry, pharmacy, and consumer channels as Théa UK.

Regional players

• Rayner Intraocular Lenses: UK-headquartered ophthalmic company with a strong cataract-surgery and ocular-pharmaceuticals footprint; comparable as a UK-based player operating in adjacent surgical and pharmaceutical ophthalmology categories served through the same hospital channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thea-uk
• Xx.com/TheaPharmaUK

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thea Pharma UK